Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression

INTRODUCTION: Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across a large cohort of solid tumor cases and correlat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Huang, Richard S.P., Murugesan, Karthikeyan, Montesion, Meagan, Pavlick, Dean C., Mata, Douglas A., Hiemenz, Matthew C., Decker, Brennan, Frampton, Garrett, Albacker, Lee A., Ross, Jeffrey S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2021
Soggetti:
Immunotherapy Biomarkers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8112409/
https://ncbi.nlm.nih.gov/pubmed/33972391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002680
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi